{"id":"sorafenib-pravastatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hand-foot skin reaction"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Muscle pain or myopathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Sorafenib inhibits multiple receptor tyrosine kinases (RAF, VEGFR, PDGFR) and serine/threonine kinases to suppress tumor growth and tumor-associated angiogenesis. Pravastatin, a HMG-CoA reductase inhibitor, lowers cholesterol and may have pleiotropic anti-inflammatory and anti-angiogenic properties that complement sorafenib's mechanism. The combination is hypothesized to improve efficacy while managing sorafenib-associated cardiovascular toxicity.","oneSentence":"This combination pairs sorafenib, a multi-kinase inhibitor that blocks tumor cell proliferation and angiogenesis, with pravastatin, a statin that may enhance anti-tumor effects and reduce cardiovascular risk.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:35:33.603Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced hepatocellular carcinoma (investigational combination)"}]},"trialDetails":[{"nctId":"NCT01903694","phase":"PHASE3","title":"Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2010-03","conditions":"Child-Pugh A Hepatocellular Carcinoma","enrollment":474},{"nctId":"NCT01075555","phase":"PHASE3","title":"Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2010-02","conditions":"Liver Cancer","enrollment":323},{"nctId":"NCT01418729","phase":"PHASE2","title":"Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced Hepatocarcinoma","status":"COMPLETED","sponsor":"Hospital Donostia","startDate":"2011-09","conditions":"Advanced Hepatocarcinoma","enrollment":216},{"nctId":"NCT01357486","phase":"PHASE2","title":"Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2011-11-14","conditions":"Hepatocellular Carcinoma, CHILD B","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["800 mg of sorafenib twice daily oral doses associated with","40 mg of pravastatin in a taken per os. Pravastatin will be taken during dinner."],"phase":"phase_3","status":"active","brandName":"Sorafenib + Pravastatin","genericName":"Sorafenib + Pravastatin","companyName":"Centre Hospitalier Universitaire Dijon","companyId":"centre-hospitalier-universitaire-dijon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination pairs sorafenib, a multi-kinase inhibitor that blocks tumor cell proliferation and angiogenesis, with pravastatin, a statin that may enhance anti-tumor effects and reduce cardiovascular risk. Used for Advanced hepatocellular carcinoma (investigational combination).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}